{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:28:24Z","timestamp":1781796504941,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The relationship between adipokine meteorin-like protein (Metrnl) and postprandial hypertriglyceridemia (PHTG) in overweight and obese populations remains unclear. This study examined the association between serum Metrnl and PHTG with normal fasting lipid profiles, using a standardized oral fat tolerance test (OFTT) to classify fat tolerance. The aim was to explore potential therapeutic targets for early obesity intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We enrolled 105 adults with normal fasting lipid profiles who met Chinese lipid management criteria for low-risk atherosclerotic cardiovascular disease (ASCVD) prevention. Participants were grouped as control (CON), overweight (OW), or obese (OB). All underwent an OFTT, with venous blood collected fasting serum Metrnl, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting insulin (FINS). Venous blood samples were collected at 1, 2, 3, and 4 hours postprandially to quantitatively analyze the dynamic changes in serum lipid profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum Metrnl showed a significant negative correlation with PHTG (r = \u20130.473, P &amp;lt; 0.001), fasting TG (r = \u20130.370, P &amp;lt; 0.001), FINS (r = \u20130.261, P = 0.007). Multivariate regression identified fasting TG as a risk factor for PHTG. Each 0.1 mmol\/L increment in fasting triglycerides was significantly associated with a 76.9% higher risk of PHTG. Metrnl was identified as protective (OR = 0.211, P\u00a0&amp;lt;\u00a00.001), the protective cutoff for Metrnl was 2.11ng\/ml. A combined model of fasting TG and Metrnl improved PHTG prediction over fasting TG or Metrnl alone, with ROC analysis showing an AUC of 0.908, sensitivity of 82.7%, and specificity of 90.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overweight and obese adults with normal fasting lipid profiles are at high risk of PHTG. Low serum Metrnl is closely associated with early lipid abnormalities and insulin resistance. Combining Metrnl with TG enhances diagnostic accuracy for PHTG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1729571","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T05:32:40Z","timestamp":1770874360000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Metrnl as a predictive biomarker for postprandial hypertriglyceridemia in overweight and obese populations"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoyu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of Endocrinology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of International Medical, Shijiazhuang People\u2019s Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yale","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of Endocrinology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojing","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of Endocrinology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of Endocrinology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of Endocrinology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of Endocrinology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyao","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of Endocrinology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","unstructured":"World Obesity Atlas 2025: New global, regional and national estimates of overweight\/obesity in adults (2000\u20132030), contributions to non-communicable diseases, and country policy responses\n          \n          \n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"Perdomo","year":"2023","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1502792","article-title":"Postprandial triglyceride-rich lipoproteins as predictors of carotid atherosclerosis in individuals with normal fasting lipid profiles: a prospective follow-up study","volume":"16","author":"Hou","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/ijmr.IJMR_1768_17","article-title":"Obesity subtypes, related biomarkers & heterogeneity","volume":"151","author":"Mayoral","year":"2020","journal-title":"Indian J Med Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0368-8","article-title":"Metrnl deficiency decreases blood HDL cholesterol and increases blood triglyceride","volume":"41","author":"Qi","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.938341","article-title":"Serum Metrnl levels are decreased in subjects with overweight or obesity and are independently associated with adverse lipid profile","volume":"13","author":"Ding","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/cells8101283","article-title":"Increased expression of meteorin-like hormone in type 2 diabetes and obesity and its association with irisin","volume":"8","author":"AlKhairi","year":"2019","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.915331","article-title":"Serum levels of meteorin-like (Metrnl) are increased in patients with newly diagnosed type 2 diabetes mellitus and are associated with insulin resistance","volume":"25","author":"Wang","year":"2019","journal-title":"Med Sci Monit"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.180","article-title":"METRNL decreases during adipogenesis and inhibits adipocyte differentiation leading to adipocyte hypertrophy in humans","volume":"41","author":"L\u00f6ffler","year":"2017","journal-title":"Int J Obes (Lond)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23473","article-title":"Changes in the expression of meteorin-like (METRNL), irisin (FNDC5), and uncoupling proteins (UCPs) after bariatric surgery","volume":"30","author":"Jamal","year":"2022","journal-title":"Obes (Silver Spring)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0231943","DOI":"10.1371\/journal.pone.0231943","article-title":"Circulating levels of Meteorin-like protein in polycystic ovary syndrome: A case-control study","volume":"15","author":"Fouani","year":"2020","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2017.268","article-title":"Opposite changes in meteorin-like and oncostatin m levels are associated with metabolic improvements after bariatric surgery","volume":"42","author":"Pellitero","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmac152","article-title":"Meteorin-like protein and asprosin levels in children and adolescents with obesity and their relationship with insulin resistance and metabolic syndrome","volume":"54","author":"Moradi","year":"2023","journal-title":"Lab Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.11.031","article-title":"Implications of circulating Meteorin-like (Metrnl) level in human subjects with type 2 diabetes","volume":"136","author":"Chung","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1190934","article-title":"2023 Chinese guideline for lipid management","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn311282-20231122-00178","article-title":"Optimization of oral fat tolerance test","volume":"40","author":"Hou","year":"2024","journal-title":"Chin J Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.12290\/xhyxzz.2024-0918","article-title":"Chinese guidelines for the clinical management of obesity (2024 edition)","volume":"16","year":"2025","journal-title":"Med J Peking Union Med Coll Hosp"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2174\/157016111795495549","article-title":"Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement","volume":"9","author":"Kolovou","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw152","article-title":"Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: A report of the American college of cardiology solution set oversight committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2020.100086","article-title":"Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review","volume":"3","author":"Toth","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3329\/jcmcta.v27i2.62368","article-title":"Study on relationship between postprandial triglycerides with overweight and obesity","volume":"27","author":"Hossain","year":"2016","journal-title":"J Chittagong Med Coll Teachers\u2019 Assoc (JCMCTA)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1017\/S0954422410000144","article-title":"A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0\u00b75 could be a suitable global boundary value","volume":"23","author":"Browning","year":"2010","journal-title":"Nutr Res Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.01.004","article-title":"Changes in non-fasting concentrations of blood lipids after a daily Chinese breakfast in overweight subjects without fasting hypertriglyceridemia","volume":"490","author":"Tian","year":"2019","journal-title":"Clin Chim Acta"},{"key":"B26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12902-025-01887-3","article-title":"Triglyceride-glucose index: a potent predictor of metabolic risk factors and eating behavior patterns among obese individuals","volume":"25","author":"El-Sehrawy","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013119.pub2","article-title":"Interventions for weight loss in people with chronic kidney disease who are overweight or obese","volume":"3","author":"Conley","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00828-1","article-title":"Programming of metabolism by adipokines during development","volume":"19","author":"Donato","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.03.065","article-title":"Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis","volume":"157","author":"Rao","year":"2014","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.627147","article-title":"Meteorin-like ameliorates \u03b2 Cell function by inhibiting \u03b2 Cell apoptosis of and promoting \u03b2 Cell proliferation via activating the WNT\/\u03b2-catenin pathway","volume":"12","author":"Hu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/db15-0274","article-title":"Adipocyte metrnl antagonizes insulin resistance through PPAR\u03b3 Signaling","volume":"64","author":"Li","year":"2015","journal-title":"Diabetes"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0147-5","article-title":"METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPAR\u03b4-dependent pathways in skeletal muscle of mice","volume":"50","author":"Jung","year":"2018","journal-title":"Exp Mol Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0680","article-title":"Metrnl alleviates lipid accumulation by modulating mitochondrial homeostasis in diabetic nephropathy","volume":"72","author":"Zhou","year":"2023","journal-title":"Diabetes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020747","article-title":"Kidney damage caused by obesity and its feasible treatment drugs","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108730","article-title":"Metrnl as a secreted protein: Discovery and cardiovascular research","volume":"263","author":"Miao","year":"2024","journal-title":"Pharmacol Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12964-024-01767-8","article-title":"Metrnl: a promising biomarker and therapeutic target for cardiovascular and metabolic diseases","volume":"22","author":"Dong","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1098570","article-title":"Meteorin-like\/Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: A comprehensive review of preclinical and clinical studies","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06459-7","article-title":"METRNL represses beta-to-alpha cell trans-differentiation to maintain beta cell function under diabetic metabolic stress in mice","volume":"68","author":"Zhou","year":"2025","journal-title":"Diabetologia"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1729571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:26:19Z","timestamp":1771928779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1729571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":39,"alternative-id":["10.3389\/fendo.2026.1729571"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1729571","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1729571"}}